Aytu BioPharma, Inc. (NASDAQ:AYTU) Short Interest Up 12.0% in August

Aytu BioPharma, Inc. (NASDAQ:AYTU) saw a significant growth in short interest in August. As of August 31st, there was short interest totalling 352,800 shares, a growth of 12.0% from the August 15th total of 314,900 shares. Based on an average daily trading volume, of 39,500 shares, the short-interest ratio is presently 8.9 days. Approximately 9.9% of the shares of the stock are sold short.

Aytu BioPharma Price Performance

NASDAQ AYTU traded up $0.03 during mid-day trading on Tuesday, reaching $1.67. 243 shares of the stock were exchanged, compared to its average volume of 65,409. The company has a quick ratio of 0.76, a current ratio of 0.92 and a debt-to-equity ratio of 0.28. Aytu BioPharma has a 1-year low of $1.38 and a 1-year high of $4.88. The business’s fifty day simple moving average is $1.73 and its 200 day simple moving average is $1.91.

Institutional Investors Weigh In On Aytu BioPharma

Hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC boosted its stake in Aytu BioPharma by 15.1% in the 1st quarter. Renaissance Technologies LLC now owns 765,469 shares of the company’s stock worth $827,000 after buying an additional 100,400 shares during the last quarter. Prudential Financial Inc. purchased a new position in Aytu BioPharma during the second quarter worth approximately $28,000. Commonwealth Equity Services LLC boosted its holdings in shares of Aytu BioPharma by 91.0% in the 3rd quarter. Commonwealth Equity Services LLC now owns 209,558 shares of the company’s stock valued at $38,000 after purchasing an additional 99,859 shares during the last quarter. Millennium Management LLC grew its stake in shares of Aytu BioPharma by 190.3% during the 4th quarter. Millennium Management LLC now owns 1,189,958 shares of the company’s stock valued at $225,000 after buying an additional 780,116 shares during the period. Finally, Dimensional Fund Advisors LP acquired a new stake in shares of Aytu BioPharma during the 1st quarter worth $106,000. Institutional investors and hedge funds own 45.09% of the company’s stock.

Analyst Ratings Changes

Separately, Maxim Group assumed coverage on Aytu BioPharma in a research report on Wednesday, August 9th. They set a “buy” rating and a $5.00 price objective for the company.

About Aytu BioPharma

Aytu Biopharma, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates into two segments Rx segment and Consumer Health segment. The Rx segment consisting of prescription pharmaceutical products sold through third party wholesalers.